Natus Medical Incorporated a leading provider of medical device solutions focused on the research, diagnosis and treatment of systemic disorders central nervous system and sensory, has entered into a definitive agreement to acquire Micromed Holding SAS ("Micromed Group" or "Micromed"), a global provider of neurophysiology solutions. The transaction is expected to close in early 2023, subject to receipt of appropriate regulatory approvals.

The Micromed acquisition will be Natus' first transaction since it was acquired by ArchiMed Group ("ARCHIMED") in July of this year. "We are pleased to make this first growth-oriented investment as an ARCHIMED portfolio company," said Thomas J. Sullivan , CEO of Natus. "The breadth and depth of clinical experience at Natus and Micromed will enable us to deliver exciting innovations to our neuroscience clients and their patients around the world."

Together, Natus and Micromed will offer customers the best-in-class portfolio of neurodiagnostic and neuromonitoring solutions. This is a legacy of more than 85 years of Natus leadership in neurodiagnostics, including brands such as NeuroWorks ® /SleepWorks ™ , Natus Quantum ® , Grass ® , Nicolet ® , Xltek ® , Embla ® , Dantec ™ TECA ® and others. , and will be combined with the full line of Micromed solutions such as BRAIN QUICK ® /MYOQUICK ® , NEUROWERK ® , SleepRT ®and MOBERG. The products will also enable a strong platform for new product development in electroencephalography (EEG), polysomnography (PSG), electromyography (EMG) and intensive care unit (ICU) monitoring through the integration of the best aspects of both portfolios. of products, including compatibility with previous versions.

"Joining the forces of the NATUS and Micromed teams with their collective knowledge and passion for neurodiagnostics and neurocritical care will result in a more comprehensive product offering and an unmatched global service and support structure for the benefit of our customers" said Austin Noll , president and leader of Natus Neuro . Mr Noll added: "Management of our new Natus Neuro team will work closely with that of Micromed, to build on Micromed's momentum in the epilepsy market in Europe and Moberg's emerging presence in ICUs."

About NATUS ( www.natus.com): NATUS offers innovative and reliable solutions to detect, diagnose and treat disorders affecting the brain, neural pathways and eight sensory nervous systems, in order to advance the standard of care and improve patient outcomes and quality of life. . The company offers advanced hardware, software, algorithms, and consumable items that deliver stimuli, collect and monitor physiological signals, and capture the body's response. With sales in more than 100 countries, Natus is a leader in neurodiagnostics, pediatric retinal imaging and hearing tests for children, as well as a leading company in hearing evaluation, hearing instrument fitting, balance and intracranial pressure monitoring. The Natus product portfolio exemplifies a legacy of innovation and leadership. Natus brands have set the standard for patient care for more than 85 years. Our products are trusted by medical professionals at university medical centers, hospitals, private practices, clinics and research laboratories around the world. Natus supports the changing needs of our customers with clinical expertise, continuing education, and exceptional technical service.

About Micromed : Founded in 1982, Micromed is a medical device company that provides neurophysiology solutions to more than 78 countries around the world. By partnering with hospitals, sleep laboratories, and research centers globally, Micromed manufactures and markets high-quality, cost-effective, and clinically relevant neurodiagnostic hardware and software to neurologists, clinicians, and researchers for use in adult and pediatric patients. Micromed's product portfolio ranges from routine, ambulatory, and video EEGs to electrocorticography (ECoG), stereoelectroencephalograms (E-EEG), polysomnography (PSG), evoked potentials (PE), electromyography (EMG), and multimodality monitoring solutions. ICU for clinical and research uses.

About ARCHIMED ( www.archimed.group): With offices in the United States and Europe, ARCHIMED is a leading investment firm focused exclusively on the healthcare industries. Its combination of operational, medical, scientific, and financial experience enables ARCHIMED to serve as a strategic and financial partner for healthcare companies in North America and Europe. Priority focus areas include biopharmaceutical products and services, life science tools, medical devices and technologies, in vitro diagnostics, healthcare IT, and consumer health. ARCHIMED helps partners internationalize, acquire, innovate and expand their products and services. During the last 20 years, ARCHIMED's leadership team has directly managed and invested in more than 80 small to large healthcare companies globally, representing more than €50 billion in combined value. ARCHIMED manages €6 billion in its various funds. Since its inception, ARCHIMED has been a committed and impact investor, both directly and through the EURÊKA Foundation.

Contacts:

Natus Medical Incorporated
InvestorRelations@Natus.com

ARCHIMED
France: Stephanie du Ché, stephanie.duche@archimed.group , +33 (0) 6 16 36 11 08;
International: David Lanchner , dlanchner@lanchner.com , +33 (0) 6 33 43 50 76

FUENTE Natus Medical Incorporated

 

Sourec:prnewswire.com

 

Report Abuse